Street Talk

Imugene in $60m cash call for new licensing deal; Bells on ticket

Sarah Thompson, Kanika Sood and Emma Rapaport

Aug 16, 2023 – 9.50am

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Imugene was leveraging a new cancer treatment licensing deal on Wednesday, asking investors for a $60 million cash injection split evenly between a placement and a share purchase plan.

Imugene executive chair Paul Hopper. Louie Douvis

Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com

Kanika Sood is a journalist based in Sydney who writes for the Street Talk column. Email Kanika at kanika.sood@afr.com.au

Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com